Fresenius Kabi Deutschland Gmbh

Beiersdorf Ag

Other

Gesellschaft Fur Biotechnologische Forschung Mbh

Fresenius Ag

Wolfram Eichner

Klaus Sommermeyer

Michele Orlando

Harald Conradt

Norbert Zander

Jurgen Hemberger

Wolfgang Meyer-Ingold

Ronald Frank

Roland Scharpf

Cornelius Jungheinrich

Heiko Mielke

Katharina Lutterbeck

Sven Frie

Klaus Langer

Albrecht Dorschner

Frank Hacket

Manfred Wirth

Hansjorg Hauser

Volker Achterberg

Elmar Kraus

Martin Schimmel

Michael Schink

Albrecht Doerschner

Jürgen Hemberger

Wilhem Dirks

Norbert Ettner

Frank Bepperling

Jens Opitz

Helmut Knoller

Franziska Hauschild

Manfred Nimtz

Wilhelm Dirks

Eckart Grabenhorst

Katharina Kock

Andreas Mitsch

Harald S Conradt

The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.

Coupling proteins to a modified polysaccharide

Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.

Conjugates of hydroxyalkyl starch and a protein

The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).

Hasylated polypeptides

The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R'NH&#x2014;R&#x2033; (II) wherein R-Rand Rare independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R&#x2032; or R&#x2033; or R&#x2032; and R&#x2033; comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.

Hydroxyalkyl starch derivatives

The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular weight substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.

Coupling low-molecular substances to a modified polysaccharide

Conjugates of hydroxyalkyl starch and a protein are provided. The conjugates are formed by a reductive amination reaction between at least one aldehyde group or keto group or hemiacetal group of the hydroxyalkyl starch or of a derivative of the hydroxyalkyl starch, and at least one amino group of the protein, so that the hydroxyalkyl starch or the derivative thereof is covalently linked to the protein via an azomethine linkage or a amino linkage. Methods of producing these conjugates and specific uses of the conjugates also are provided.

Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination

Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.

The invention relates to compounds, comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate, whereby HAS and an active agent are reacted in a reaction medium, characterised in that the reaction medium is water or a mixture of water and an organic solvent, comprising at least 10 wt. % water.

Conjugates of hydroxyalkyl starch and an active agent

Use of hemoglobin derivatives for determining plasma and/or blood volume

The invention relates to novel wound coverings with which interfering factors of the wound healing process can be removed from the wound fluid of chronic wounds in a controlled manner and the normal healing process is promoted.

Wound coverings for removal of interfering factors from wound fluid

Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers

Multicistronic expression units allow the equimolar expression of the genes located in the corresponding cistrons. These expression units are particularly suitable for the recombinant production of proteins composed of two or more polypeptide subunits.

Multicistronic expression units and their use

Cell adhesion peptides for modifying the adhesion capacity of eukaryotic

Growing community of inventors

Butzbach, Germany

Wolfram Eichner